Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018.
Sign Up to like & getrecommendations! Published in 2019 at "Vaccine"
DOI: 10.1016/j.vaccine.2019.08.087
Abstract: BACKGROUND In March 2011, the U.S. Food and Drug Administration licensed adenovirus type 4 and type 7 vaccine, live, oral (Barr Labs, Inc.) (adenovirus vaccine) for use in military personnel 17 through 50 years of age.… read more here.
Keywords: adverse event; october 2011; following adenovirus; adenovirus vaccine ... See more keywords
Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection
Sign Up to like & getrecommendations! Published in 2021 at "Vaccines"
DOI: 10.3390/vaccines9030299
Abstract: Adenovirus-based vaccines are demonstrating promising clinical potential for multiple infectious diseases, including COVID-19. However, the immunogenicity of the vector itself decreases its effectiveness as a boosting vaccine due to the induction of strong anti-vector neutralizing… read more here.
Keywords: vaccine doses; adenovirus vaccine; low adenovirus; antibody ... See more keywords